Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Kidney Fibrosis Treatment Market?

The market for kidney fibrosis treatment has experienced significant growth in the past few years. Its total value is projected to rise from $6.93 billion in 2024 to $7.58 billion in 2025, marking an annual compound growth rate (CAGR) of 9.4%. This historical growth is due, in part, to increased investment in R&D for fibrosis targeting therapies, government-funded initiatives focused on kidney disease management, a rise in patient awareness regarding kidney transplant and fibrosis treatment options, improved healthcare infrastructure, and an increase in the aging population.

What Growth Rate Is Forecasted for the Kidney Fibrosis Treatment Market by 2029?

Forecasted to observe a rapid expansion in the coming years, the kidney fibrosis treatment market size is predicted to reach $10.78 billion by 2029, with a compound annual growth rate (CAGR) of 11.7%. This growth during the forecast period is linked to a rising prevalence of chronic kidney illness, an escalating demand for cutting-edge therapies to manage renal fibrosis, increasing awareness of kidney fibrosis detection at early stages, the growing implementation of personalized medicine in treating kidney disease, as well as the escalating frequency of both diabetes and hypertension. Prominent trends expected in the forecast period encompass technological enhancements in early detection and diagnostic tools, advancements in gene therapy, the integration of technology in telemedicine and remote monitoring, improvements in stem cell therapies, and progress in drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

Which Key Companies Are Shaping the Future of the Kidney Fibrosis Treatment Market?

Major companies operating in the kidney fibrosis treatment market are F. Hoffman-La Roche Ltd., Merck & Co. Inc., Bayer AG, AstraZeneca PLC, Cara Therapeutics Inc., Gilead Sciences Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Chinook Therapeutics Inc., Reata Pharmaceuticals Inc., Akebia Therapeutics Inc., Travere Therapeutics Inc., Insilico Medicine Inc., Tvardi Therapeutics Inc., ProKidney LLC, Alentis Therapeutics AG, La Jolla Pharmaceutical Company, Galecto Biotech AB, Purespring Therapeutics Inc.

Which Factors Are Driving Demand in the Kidney Fibrosis Treatment Industry?

The escalating occurrence of chronic kidney diseases is set to drive the expansion of the kidney fibrosis treatment market in the future. The gradual dysfunction of the kidney over time, commonly referred to as chronic kidney disease (CKD), often results from issues such as diabetes or hypertension, leading to accumulation of waste products in the body. The surge in the prevalence of CKD is primarily due to increasing rates of diabetes, which can damage blood vessels in the kidney and compromise its filtration capacity. By targeting tissue scarring in the kidney, reducing inflammation, and decelerating kidney damage progression, kidney fibrosis treatment proves beneficial for CKD patients in conserving kidney function. For instance, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, attested in May 2024 that an estimated 14% of U.S. adults, translating to about 35.5 million individuals, are purportedly suffering from chronic kidney diseases. Hence, the growth rate of the kidney fibrosis treatment market is being propelled by the rising prevalence of chronic kidney diseases. The expansion of the kidney fibrosis treatment market is also being spurred by increasing clinical trial activities in pursuit of innovative and personalized therapies. Clinical trials are human research studies aimed at estimating the safety, effectiveness and possible adverse effects of medical treatments or interventions. The drive for personalized and ground-breaking treatments that calls for in-depth safety and efficiency testing results in ever-increasing clinical trials. The presence of a defined target area for novel anti-fibrotic therapies testing by kidney fibrosis treatment contributes to these clinical trials, allowing researchers to assess the ability of new drugs to decelerate or reverse kidney damage. In an example, the Association of the British Pharmaceutical Industry, a UK-based trade association, reported in November 2023 that the annual recruitment to industry clinical trials in the UK showed a 15% rise, moving from 36,722 participants in 2021-22 to 42,088 in 2022-23. Hence, the escalating number of clinical trials fosters the growth of the kidney fibrosis treatment market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24271&type=smp

How Is the Kidney Fibrosis Treatment Market Segmented by Several Divisions?

The kidney fibrosis treatment market covered in this report is segmented –

1) By Treatment Type: Angiotensin-Converting Enzyme (Ace) Inhibitors, Angiotensin Ii Receptor Blockers (Arbs), Pirfenidone, Renin Inhibitors, Vasopeptidase Inhibitors, Other Treatment Types

2) By Diagnosis: Blood Tests, Urine Tests, Imaging Tests, Kidney Biopsy

3) By Application: Chronic Kidney Diseases, Kidney Cancer Treatment, Other Applications

4) By End-User: Clinics, Research Center, Hospitals

Subsegments:

1) By Angiotensin-Converting Enzyme (Ace) Inhibitors: Enalapril, Captopri, Lisinopril, Ramipril

2) By Angiotensin Ii Receptor Blockers (Arbs): Losartan, Telmisartan, Valsartan, Irbesartan

3) By Pirfenidone: Branded Pirfenidone, Generic Pirfenidone

4) By Renin Inhibitors: Aliskiren, Experimental Renin Inhibitors

5) By Vasopeptidase Inhibitors: Omapatrilat, Sampatrilat

6) By Other Treatment Types: Anti-Inflammatory Agents, Stem Cell Therapy, Antifibrotic Agents Under Clinical Trials, Gene Therapy

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/kidney-fibrosis-treatment-global-market-report

Which Regions Are Driving Growth in the Kidney Fibrosis Treatment Market?

North America was the largest region in the kidney fibrosis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kidney fibrosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/customise?id=24271&type=smp

This Report Delivers Insight On:

1. How big is the kidney fibrosis treatment market, and how is it changing globally?

2. Who are the major companies in the kidney fibrosis treatment market, and how are they performing?

3. What are the key opportunities and risks in the kidney fibrosis treatment market right now?

4. Which products or customer segments are growing the most in the kidney fibrosis treatment market?

5. What factors are helping or slowing down the growth of the kidney fibrosis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model